Description
This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.
Location: SIMR (Sacramento/Valley Area, Roseville, and Auburn)
Please contact: SIMR@sutterhealth.org about Metastatic (AstraZeneca D533AC00001 MONETTE)
Principal Investigator
Co-Investigator(s)
Sivakumar Reddy, M.D., Vijay Suhag, M.D., Brian K. Kim, M.D, Jaspreet K Dhillon, Medical Oncologist, Kristin N. Arreola, M.D., Kristie A. Bobolis, M.D., Rajeswari Chellappah, M.D., Dron Gauchan, MD
Related Studies
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.
Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator